Operating
Accretion (amortization) of discounts and premiums on investments
Neurocrine Biosciences Accretion (amortization) of discounts and premiums on investments decreased by 35.0% to $1.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 71.7%, from $4.60M to $1.30M. Over 4 years (FY 2021 to FY 2025), Accretion (amortization) of discounts and premiums on investments shows an upward trend with a 14.5% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
Reflects the yield characteristics of the investment portfolio; changes are driven by interest rate environments and bond pricing.
Detailed definition
This reflects the non-cash adjustment for the difference between the purchase price and the par value of fixed-income se...
Peer comparison
Common in insurance and banking sectors where large investment portfolios are held.
Metric ID:
bac_accretion_amortization_investmentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$1.85M | -$1.85M | -$1.85M | -$925.00K | -$925.00K | -$925.00K | -$925.00K | $2.10M | $3.90M | $6.00M | $6.30M | $7.10M | $7.00M | $6.50M | $5.60M | $4.60M | $3.40M | $2.70M | $2.00M | $1.30M |
| QoQ Change | — | +0.0% | +0.0% | +50.0% | +0.0% | +0.0% | +0.0% | +327.0% | +85.7% | +53.8% | +5.0% | +12.7% | -1.4% | -7.1% | -13.8% | -17.9% | -26.1% | -20.6% | -25.9% | -35.0% |
| YoY Change | — | — | — | — | +50.0% | +50.0% | +50.0% | +327.0% | +521.6% | +748.6% | +781.1% | +238.1% | +79.5% | +8.3% | -11.1% | -35.2% | -51.4% | -58.5% | -64.3% | -71.7% |
Range-$1.85M – $7.10M
CAGR-7.2%
Avg YoY Growth+160.1%
Median YoY Growth+50.0%
Current Streak8 quarters decline
Accretion (amortization) of discounts and premiums on investments at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's accretion (amortization) of discounts and premiums on investments?
- Neurocrine Biosciences (NBIX) reported accretion (amortization) of discounts and premiums on investments of $1.30M in Q1 2026.
- How has Neurocrine Biosciences's accretion (amortization) of discounts and premiums on investments changed year-over-year?
- Neurocrine Biosciences's accretion (amortization) of discounts and premiums on investments decreased by 71.7% year-over-year, from $4.60M to $1.30M.
- What is the long-term trend for Neurocrine Biosciences's accretion (amortization) of discounts and premiums on investments?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's accretion (amortization) of discounts and premiums on investments has grown at a 14.5% compound annual growth rate (CAGR), from -$7.40M to $12.70M.
- What does accretion (amortization) of discounts and premiums on investments mean?
- Non-cash adjustments to the value of investment securities held by the company.